Director at Abbott (NYSE: ABT) buys 2,000 shares in open market
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Abbott Laboratories director John G. Stratton reported an open-market purchase of 2,000 common shares on May 7, 2026 at a price of $86.82 per share. Following this transaction, he directly owns 23,319 common shares of Abbott Laboratories.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,000 shares ($173,640)
Net Buy
1 txn
Insider
Stratton John G
Role
null
Bought
2,000 shs ($174K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common shares without par value | 2,000 | $86.82 | $174K |
Holdings After Transaction:
Common shares without par value — 23,319 shares (Direct, null)
Footnotes (1)
Key Figures
Shares purchased: 2,000 shares
Purchase price: $86.82 per share
Shares owned after transaction: 23,319 shares
+2 more
5 metrics
Shares purchased
2,000 shares
Open-market purchase on May 7, 2026
Purchase price
$86.82 per share
Open-market buy of Abbott common shares
Shares owned after transaction
23,319 shares
Director’s direct holdings following the purchase
Buy transactions in filing
1 transaction
Form 4 transaction summary buyCount
Net buy/sell shares
2,000 shares net-buy
Form 4 transactionSummary netBuySellShares
Key Terms
open-market purchase, Common shares without par value, Form 4, direct ownership
4 terms
open-market purchase financial
"transaction_action: "open-market purchase" for 2,000 common shares"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Form 4 regulatory
"INSIDER FILING DATA (Form 4) describing the transaction"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
direct ownership financial
"direct_or_indirect: "D" and ownership_type: "direct""
FAQ
What insider transaction did Abbott Laboratories (ABT) report?
Abbott Laboratories reported that director John G. Stratton made an open-market purchase of 2,000 common shares. The transaction took place on May 7, 2026, and was reported on a Form 4 insider trading filing.
What are John G. Stratton’s total Abbott (ABT) holdings after the transaction?
After the reported purchase, John G. Stratton directly owns 23,319 Abbott common shares. This total reflects his position immediately following the 2,000-share open-market buy disclosed in the Form 4 filing.
Was the Abbott (ABT) insider transaction a purchase or a sale?
The insider transaction was a purchase. The Form 4 lists a transaction code “P” and describes it as an open-market purchase of 2,000 Abbott common shares at $86.82 per share, increasing the director’s direct holdings.
Does the Abbott (ABT) Form 4 involve any derivative securities or options?
No, the Form 4 shows only a non-derivative transaction in common shares without par value. The derivativeSummary section is empty, indicating no reported option exercises, conversions, or other derivative-related activities in this filing.
Is John G. Stratton’s Abbott (ABT) ownership direct or indirect?
John G. Stratton’s reported ownership in this filing is direct. The transaction is coded as direct ownership, and the nature of ownership field does not indicate any trust, LLC, or other indirect holding structure for these 23,319 common shares.